NIH Alzheimer’s Trial Based On Industry Support, Not Science – Public Citizen
Executive Summary
Public Citizen's Health Research Group is objecting to an NIH Alzheimer's prevention trial of Pfizer/Pharmacia's Celebrex and Bayer's Naprosyn on the grounds that the drugs have not demonstrated activity in preventing the disease
You may also be interested in...
Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial
The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues
Naproxen Heart Concerns Surface In Halted NIH Alzheimer’s Trial
The OTC industry is taking a wait-and-see approach regarding concerns about cardiovascular risks of naproxen (Bayer's Aleve) and other older NSAIDs rising in the wake of COX-2-related safety issues
Merck COX-2 Cardiovascular Safety Studies Will Enroll 30,000 Subjects
Merck plans to enroll approximately 30,000 subjects in cardiovascular safety trials to resolve issues raised about the CV effects of its COX-2 inhibitors Vioxx (rofecoxib) and Arcoxia (etoricoxib)